| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,598 |
1,205 |
$41K |
| 87631 |
|
522 |
433 |
$33K |
| 87640 |
|
1,132 |
975 |
$29K |
| 87641 |
|
1,078 |
894 |
$27K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,098 |
915 |
$27K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
319 |
285 |
$23K |
| 87634 |
|
418 |
357 |
$21K |
| 87481 |
|
721 |
609 |
$18K |
| 87581 |
|
575 |
473 |
$17K |
| 87541 |
|
523 |
434 |
$16K |
| 87498 |
|
524 |
435 |
$16K |
| 87653 |
|
566 |
502 |
$13K |
| 87529 |
|
405 |
368 |
$12K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
403 |
366 |
$11K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
405 |
368 |
$11K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
402 |
365 |
$11K |
| 87500 |
|
445 |
390 |
$10K |
| 87563 |
|
565 |
501 |
$10K |
| 87511 |
|
402 |
365 |
$9K |
| 87486 |
|
114 |
88 |
$4K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
36 |
23 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
68 |
56 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
18 |
13 |
$570.52 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
31 |
20 |
$0.00 |